Majd B. Aboona

Majd B. Aboona

Auto-generated profile, based on publicly available information

Majd B. Aboona

Department of Internal Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Gut
Verified
Journal Article
Closed access
PDF file
ECElina En Li Cho
Elina En Li Cho
CAChong Zhe Ang
Chong Zhe Ang
JQJingxuan Quek
Jingxuan Quek
CFClarissa Elysia Fu
Clarissa Elysia Fu
LLLincoln Kai En Lim
Lincoln Kai En Lim
RLRohit Loomba
Rohit Loomba
Introduction: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM. Methods: MEDLINE and Embase databases were searched from inception until 13 February 2023. The primary outcomes were the prevalence of NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis in people with T2DM. A generalised linear mixed model with Clopper-Pearson intervals was used for the analysis of proportions with sensitivity analysis conducted to explore heterogeneity between studies. Results: 156 studies met the inclusion criteria, and a pooled analysis of 1 832 125 patients determined that the prevalence rates of NAFLD and NASH in T2DM were 65.04% (95% CI 61.79% to 68.15%, I2=99.90%) and 31.55% (95% CI 17.12% to 50.70%, I2=97.70%), respectively. 35.54% (95% CI 19.56% to 55.56%, I2=100.00%) of individuals with T2DM with NAFLD had clinically significant fibrosis (F2–F4), while 14.95% (95% CI 11.03% to 19.95%, I2=99.00%) had advanced fibrosis (F3–F4). Conclusion: This study determined a high prevalence of NAFLD, NASH and fibrosis in people with T2DM. Increased efforts are required to prevent T2DM to combat the rising burden of NAFLD. PROSPERO registration number: CRD42022360251.

8 April 2024 in Hepatology
Verified
Journal Article
Closed access
PDPojsakorn Danpanichkul
Pojsakorn Danpanichkul
MAMajd B. Aboona
Majd B. Aboona
BSBanthoon Sukphutanan
Banthoon Sukphutanan
SKSiwanart Kongarin
Siwanart Kongarin
KDKwanjit Duangsonk
Kwanjit Duangsonk
KWKarn Wijarnpreecha
Karn Wijarnpreecha
Objective: The worldwide burden of cancer is increasing in younger populations. However, the epidemiology of primary liver cancer remains understudied in young adults compared to other cancer forms. Methods: This study analyzed data from the Global Burden of Disease (GBD) study between 2010 and 2019 to assess the age-standardized incidence, mortality, and disability-adjusted life years (DALYs) associated with primary liver cancer in the young (15–49 y), stratified by region, nation, sociodemographic index, and sex. Results: The study found a global estimate of 78,299 primary liver cancer cases, 60,602 deaths, and 2.90 million DALYs in the young population. The Western Pacific region exhibited the highest burden in 2019, showing the most significant increase compared to other regions between 2010–2019. More than half of countries worldwide have undergone an increase in primary liver cancer incidence rates in young adults. Around 12.51% of deaths due to primary liver cancer occur in young individuals. Throughout the study period, there was a significant decline in primary liver cancer mortality due to most etiologies, except for metabolic dysfunction-associated steatotic liver disease (MASLD)-attributable primary liver cancer (annual percentage change [APC] +0.87%, 95% confidence interval 0.70–1.05%) and alcohol-attributable primary liver cancer (APC +0.21%, 95% confidence interval 0.01–0.42%). Limitations of the GBD database include reliance on the quality of primary data and possible underestimation of alcohol consumption. Conclusion: Over the past decade, there has been a marked increase in the burden of primary liver cancer, especially that originating from steatotic liver disease. This trend calls for the development of urgent and comprehensive strategies to mitigate this rising burden globally. Export

22 August 2024 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MAMajd B. Aboona
Majd B. Aboona
PDPojsakorn Danpanichkul
Pojsakorn Danpanichkul
VCVincent Chen
Vincent Chen
PRPooja Rangan
Pooja Rangan
DKDonghee Kim
Donghee Kim
KWKarn Wijarnpreecha
Karn Wijarnpreecha

26 February 2024 in Liver International
Verified
Journal Article
Closed access
MAMajd B. Aboona
Majd B. Aboona
CFClaire Faulkner
Claire Faulkner
PRPooja Rangan
Pooja Rangan
CNCheng Han Ng
Cheng Han Ng
DHDaniel Huang
Daniel Huang
KWKarn Wijarnpreecha
Karn Wijarnpreecha

23 May 2025 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
LGLeith Ghani
Leith Ghani
MAMajd B. Aboona
Majd B. Aboona
CFClaire S. Faulkner
Claire S. Faulkner
PRPooja Rangan
Pooja Rangan
MRMoises Nevah Rubin
Moises Nevah Rubin
KWKarn Wijarnpreecha
Karn Wijarnpreecha

1 January 2022 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
ETErica Turse
Erica Turse
MAMajd Aboona
Majd Aboona
ECEricka Charley
Ericka Charley
AFArnold Forlemu
Arnold Forlemu
TBTessa Bowie
Tessa Bowie
ANAbdul Nadir
Abdul Nadir
Background: With the rising incidence of hepatocellular carcinoma (HCC), ongoing efforts should be focused on providing equitable and state-of-the-art care to patients. Purpose: The aim of this study was to determine the survival of patients with HCC seen at a high-proportion Safety Net Hospital (h-SNH), where loco-regional therapy and hepatology services are available and liver transplantation (LT) is referred to outside facilities. Patients and Methods: A retrospective cohort study was conducted on all patients with HCC seen at Valley Wise Health Center (VWHC) over a ten-year period. Clinical variables, treatment modalities, survival duration, hospice, and LT referrals of 161 patients were collected from the medical records. Survival analysis was used to determine the relationship of clinically relevant variables and survival among patients with HCC. A Log rank test was used to compare univariate variables. A Cox regression analysis was used to compare and control for multiple variables. Results: Of the 161 patients included in the study, 33% were uninsured. The median age was 59 (21 to > 89) years with 47% Hispanic, 31% Caucasian, 15% African American and 7% other races included for the analysis. The median survival for the cohort was 20.1 months. In the multivariate model, insurance status, final MELD, tumor within the Milan criteria and having received treatment for HCC were associated with survival. Surveillance for HCC was associated with HCC in the univariate analysis, but not in the multivariable model. Thirty percent of patients were referred for LT and 1.25% of the entire cohort received it. Conclusion: Despite the availability of treatment modalities available for HCC at VWHC and the option of liver transplantation for appropriate candidates at outside centers, OS was less than reported from programs with on-site liver transplant programs. Reasons for lower survival in centers without liver transplant programs should be further studied.